Journal of Cell Science & Therapy
Open Access

Navigating the Immune Roadblocks in Central Nervous System Stem Cell Therapies

Birgit Kruse^{* *}Correspondence: Birgit Kruse, Department of Natural Sciences, Northwest Missouri State University, Maryville, USA, Email:

Author info »

Description

Many neurodegenerative diseases, such as Alzheimer's disease, which cause a significant loss of neuronal cells, can affect the central nervous system. As stem cells may develop into a variety of cell types, they are excellent for treating these diseases. Despite some encouraging findings in animal models for a variety of brain illnesses, stem cell treatment has not yet been used in human clinical settings. The immunological response that stem cell transplants trigger is a significant barrier to the introduction of stem cell treatment into clinical settings. This study is focused on immunological and associated barriers to stem cell treatments for illnesses of the central nervous system. Allogeneic grafts, which include the transplantation of cells, tissue, or organs between different people, usually result in the rejection of the donor material as a result of a concomitant humoral and cellular immune response. Contrarily, autologous grafts those taken from the same person or their identical twin—rarely experience rejection. Human graft rejection is influenced by more than 40 genes. The ones that encode the Major Histocompatibility Complex I and Major Histocompatibility Complex II are by far the most significant (MHC I and MHC II). Human Leukocyte Antigens (HLAs) are another name for MHC I and MHC II in humans (HLAs). The extracellular domain of MHC I and MHC II proteins, which are produced on the surface of cells, include tiny clefts that bind to short peptides. Two different proteins, 2- microglobulin and a transmembrane MHC protein, make up MHC I. Two transmembrane MHC proteins make up MHC II. Whereas MHC II molecules have an open-ended groove that binds to bigger peptides that are 10-30 residues long, MHC I molecules can only attach to peptides that are 8 to 11 residues in length. Yet, the ideal peptide length for attaching to MHC II is between 18 and 20 residues. Both MHC I and MHC II can bind a range of peptides in their clefts, despite the fact that they can only bind to one peptide at a time. The Central Nervous System (CNS), where they are expressed on both glia and neurons in vivo, is one area of the body where MHC I proteins are expressed on nearly all cells. MHC I proteins are abundant at synapses both pre- and postsynaptically, on the surface of both axons and dendrites, and are important in controlling neurite development.

The Central Nervous System (CNS), where they are expressed on both glia and neurons in vivo, is one area of the body where MHC I proteins are expressed on nearly all cells. MHC I proteins are abundant at synapses both pre- and postsynaptically, on the surface of both axons and dendrites, and are important in controlling neurite development. The MHC II-peptide complexes are subsequently produced on the surface of the APCs, where they can bind to TCRs on helper T cells that are positive for Cluster of Differentiation 4 (CD4). Several proteins, including MHC I and MHC II, will be recognized as foreign when cells from an allogeneic donor are transplanted into a host animal. In order to activate cytotoxic T cells, these proteins will be digested by host dendritic cells and other APCs and displayed on MHC I proteins. To activate helper T cells, additional peptides will be given on MHC II proteins. TCRs can attach directly to allogeneic MHC from the graft that includes either self or foreign peptides in addition to binding to self-MHC molecules harbouring foreign peptides. Allogeneic MHC-peptide complexes have a structure that is similar to self-MHC-foreign peptide complexes. APCs in the host may phagocytose and process cells that express MHC I and/or MHC II. Due to their great polymorphism, MHC proteins would be recognized as foreign by host lymphocytes. A comparable graft against host reaction will also be seen if the transplant comprises lymphocytes. Similar rejection occurs after allogeneic Brain transplants, although the adaptive immune response is slower and less potent. Tight connections between endothelial cells that lining blood arteries keep the brain and eye away from the blood. The Blood-Brain Barrier (BBB) and blood- retina barrier are created as a result. The blood and cerebrospinal fluid are separated by a third barrier (blood-cerebrospinal fluid barrier). The choroid plexus secretes cerebrospinal fluid into the ventricles. Immune monitoring for prospective infections is not absent in the Brain. For instance, immune-suppressed individuals had higher rates of CNS infections. Brain tissue that would be accepted by uninitiated animals is rejected if the host had already been exposed to alloantigens outside the CNS. This implies that T cells that have been activated outside of the Brain enter the CNS and launch an immunological response. Earlier studies have demonstrated that transplanted brain tissue did not trigger an immunological reaction. Tolerance or immune privilege was used to describe this. It was believed that the CNS's isolation from the lymphatic and blood systems prevented it from mounting an immune response.

Conclusion

If the donor and recipient are adequately matched in the MHC region and immune suppression is used, organ transplants have proven fairly effective. Even though the immune response in the Brain is mild in comparison to the rest of the body, allogeneic and xenogeneic tissues transplanted there eventually get rejected in the absence of immune suppression. Intracerebral transplantation faces a variety of difficulties. Moreover, steps must be made to prevent inflammation and tissue edoema from causing additional harm to the brain. Anti-inflammatory and immunosuppressive medication are needed for this. Finding efficient treatments that can control secondary issues brought on by the injury to the host tissue and the presence of foreign cells that can also cross the BBB is another challenge in the treatment of CNS illnesses with brain transplants. Non-steroidal Anti- inflammatory Drugs (NSAIDs) and peptides are examples of small compounds that can diffuse over the BBB, however this process is not particularly effective. Larger molecules, such as humanized antibodies, cannot pass through the BBB unaltered. Before brain transplants may be utilized to treat CNS illnesses successfully, further study is required.